SEARCH · PubMed Health

Results for “Community setting”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 541 records · Page 30Linked to original sources

PubMed1994

Canadian study of health and aging: study methods and prevalence of dementia.

OBJECTIVE: To estimate the prevalence of dementia and its subtypes by sex and age group for five regions of Canada. DESIGN: Prevalence survey. SETTING: Community and institutional settings in Canada, excluding those in the two territories, Indian reserves and military units. PARTICIPANTS: Representative sample of people aged 65 and over interviewed between February 1991 and May 1992. Those in the community (9008 subjects) were chosen randomly from medicare lists in nine provinces or from the Enumeration Composite Record in Ontario. People in institutions (1255) were randomly selected from residents in stratified random samples of institutions in each region. INTERVENTIONS: Screening with the Modified Mini-Mental State (3MS) Examination to identify cognitive impairment. Clinical examination of all those in institutions, those in the community with a 3MS score of less than 78 and a sample of those in the community with a 3MS score of 78 or more to diagnose dementia. Dementia and Alzheimer's disease were defined according to established criteria. MAIN OUTCOME MEASURES: Prevalence of dementia of all types, by region, sex and age group, the estimated number of cases in the population by type of dementia and the age-standardized rate per 1000 population. RESULTS: The prevalence estimates suggested that 252,600 (8.0%) of all Canadians aged 65 and over met the criteria for dementia (95% confidence interval [CI] 236,800 to 268,400). These were divided roughly equally between the community and institutional samples; the female:male ratio was 2:1. The age-standardized rate ranged from 2.4%, among those aged 65 to 74 years, to 34.5%, among those aged 85 and over. The corresponding figures for Alzheimer's disease were 5.1% overall (161,000 cases; 95% CI 148,100 to 173,900), ranging from 1.0% to 26.0%; for vascular dementia it was 1.5% overall, ranging from 0.6% to 4.8%. If the prevalence estimates remain constant, the number of Canadians with dementia will rise to 592,000 by 2021. CONCLUSIONS: These Canadian estimates of the prevalence of dementia fall toward the upper end of the ranges in other studies, whereas the estimates for Alzheimer's disease fall in the middle of the ranges. This may suggest an unusual balance between Alzheimer's and other forms of dementia in the Canadian population.

Age Distribution↗

PubMed1994

Net economic costs of dementia in Canada.

OBJECTIVE: To estimate the net economic costs of dementia in Canada in 1991 by comparing costs related to elderly patients with dementia with those related to elderly people without dementia. DESIGN: Cost-of-illness study. DATA SOURCES: Most of the data analysed in this study were from the Canadian Study of Health and Aging (CSHA), in which 10,263 Canadians aged 65 years and over were randomly selected, surveyed and, when appropriate, given clinical examinations. Data on patients with dementia and on people without cognitive impairment (control subjects) were used for this analysis. Data on activities of daily living (ADLs) were taken from a separate study under the CSHA, in which the principal caregivers of the subjects in the prevalence study were interviewed. SETTING: Community and institutional settings in Canada, excluding those in the territories. PATIENTS: All patients with dementia 65 years and older as determined from the CSHA. Patients with dementia under 65 were also considered. OUTCOME MEASURES: Costs of paid and unpaid services in the community, care in long-term care institutions, drugs, hospitalization, diagnosis and research. RESULTS: The total annual net cost of dementia was estimated to be over $3.9 billion. Costs associated with elderly patients in the community were estimated to be $1.25 billion ($615 million for paid services, $636 million for unpaid services), whereas costs for patients in long-term care institutions were $2.18 billion. Costs were about $74 million for drugs, hospitalization and diagnosis, $10 million for research and $389 million related to patients under age 65. CONCLUSION: The annual net economic cost of dementia in Canada is at least $3.9 billion. The most significant component of the total cost was for care in long-term care institutions and for assistance with ADLs by professionals, family and friends in the community. The economic burden of dementia is significant not only for patients, their families and friends, but also for society.

Aged↗

PubMed2003

A heart-healthy and "stroke-free" world through policy development, systems change, and environmental supports: a 2020 vision for sub-Saharan Africa.

The vision of a heart-healthy and "stroke-free" world is achievable through the aggressive prevention and control of cardiovascular risk factors. In sub-Saharan Africa, a region plagued by infectious and parasitic diseases, nutritional deficiencies, and excessive maternal and perinatal morbidity and mortality, the prevention of cardiovascular diseases (CVD) and risk factors is rarely on the public health agenda. In Africa, however, as recently documented by the World Health Organization's Africa Regional Office, CVD and other chronic non-communicable diseases are on the increase and already represent a significant burden on public health services. Age-specific mortality and morbidity associated with CVD and chronic diseases are higher in sub-Saharan Africa than in established market economies. Correspondingly, adverse trends in risk factor profile are beginning to appear especially in many urban centers in sub-Saharan Africa. Addressing and reversing these trends will take more than just targeting individuals and their behaviors and lifestyle choices. More importantly, to support heart-healthy choices, emphasis must be placed on policy development, systems changes, and issues in the social environment factors such as the need to strengthen legislation and regulatory mechanisms, which control the leading risk factors (eg, tobacco, physical inactivity, and poor nutrition). We must develop and conduct heart-healthy and "stroke-free" initiatives to take place in diverse community settings: schools, worksites, communities, and healthcare systems. In addition, public health capacity and infrastructure must be strengthened to provide adequate surveillance and the assurance that best practices are implemented. Action is needed to integrate health promotion, risk factor control and disease prevention within the primary healthcare setting. Above all, population-based approaches must be used to promote education and awareness of the importance of CVD risk factors. In sub-Saharan Africa, where most people have no more than one CVD risk factor, a unique opportunity exists for primordial prevention, ie, preventing the development of risk factors in the first place. The policy and environmental change strategies discussed provide a road map to a heart-healthy and "stroke-free" future.

Africa South of the Sahara↗

PubMed2006

The role of public health agencies in providing access to adolescent drug treatment services.

PURPOSE: To examine the role of public health agencies (PHAs) in providing access to drug treatment services for adolescents by describing the proportion of youth who obtain access to these services through PHA involvement in school health clinics, juvenile drug courts, and other community agencies. METHODS: Analysis of cross-sectional telephone interview data collected from 1999-2003 from a national sample of 1793 PHA key informants from communities surrounding schools in the nationally representative Monitoring the Future (MTF) study of 8th, 10th and 12th grade students. RESULTS: Fifty-eight percent of youth in the MTF sample were served by PHAs that participated in some way in school health clinics, with 30% served by PHAs that provided resources for drug treatment in schools. Twenty-nine percent of youth were served by PHAs involved in juvenile drug court (JDC) programs, 23% by PHAs acting as JDC referral agencies, and 13% by PHAs providing direct JDC drug assessment, treatment and monitoring services. In addition, 44% of youth were served by PHAs providing drug treatment resources in community settings. Treatment access for youth through PHAs varied by region, race/ethnicity, urbanicity, community income level, and youth population density. The largest variation occurred in access via JDC programs. CONCLUSIONS: PHAs may help bridge gaps between drug treatment need and service provision for adolescents who need access to drug treatment services. Strengthening the linkages between PHAs and schools, juvenile drug courts, and other community settings may serve to increase youth access to drug treatment.

Adolescent↗

PubMed1996

Assertive community treatment of severe mental illness: a Canadian experience.

The study assessed one-year outcomes for 110 clients with serious mental illness who were randomly assigned to an assertive community rehabilitation program that provides psychiatric rehabilitation services in community settings or to hospital-based rehabilitation programs. Key elements of the community program include a multidisciplinary team on call 24 hours a day, in vivo treatment, and instruction and assistance in basic living skills. Data from client interviews after one year of service were used to assess clients' quality of life, satisfaction with services, and psychopathology. Clients in the assertive community rehabilitation program were more likely to be maintained in community settings and reported better quality of life than clients in the hospital-based programs.

Activities of Daily Living↗

PubMed2005

[Prevalence of vancomycin-resistant enterococci in hospital and community environment.].

AIM OF THE STUDY: The presented study aimed at determining the prevalence of vancomycin-resistant enterococci (VRE) in rectal swabs taken from both patients in the Teaching Hospital in Olomouc (THO), Czech Republic, and subjects from the community setting of the hospital's catchment area. MATERIALS AND METHODS: Between July 1, 2002 and July 1, 2003, rectal swabs were taken from the THO patients as well as individuals from the community catchment area to be utilized for isolating and identifying enterococci and their suscetibility to antibiotics. Vancomycin resistance phenotypes were verified by PCR detection of vanA, vanB, vanC1 and vanC2 genes. A molecular biology analysis was performed in VanA Enterococcus faecium strains. To determine the relationship of strains, macrorestriction analysis of the total chromosomal DNA digested with SmaI restriction endonuclease was used. RESULTS: During the observed period, 2,157 rectal swabs from the hospitalized patients and 4,874 rectal swabs from the subjects in community setting were examined. In total, 27 VRE of hospital origin and 13 community-population strains were isolated. The prevalence of VRE in the gastrointestinal tract was 2.3 % in the hospitalized patients and 0.6 % in the community subjects. The prevailing strains were Enterococcus faecium VanA (70.4 %) in the VRE of hospital origin and Enterococcus gallinarum VanC (46.2 %) in the community VRE. Mutual comparison between the hospital and community VRE showed no similarity. CONCLUSION: In the Czech Republic, VRE were proved both in community and hospital settings. Their prevalence in rectal swabs is low and does not exceed the values reported in other European countries. The author describes the chief characteristics of the most important quinolone antibiotics, including preparations either in their development stage or whose development has been prematurely interrupted because of adverse side-effects. The list includes all preparations that are or were temporarily registered in the Czech Republic.

Anti-Bacterial Agents↗

PubMed1995

Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging.

STUDY OBJECTIVE: To describe a population that was categorized as "cognitively impaired not demented" (CIND) and to examine the utility of some of the proposed criteria for describing this degree of cognitive impairment. DESIGN: Population-based prevalence study of dementia in those subjects who were 65 years and older. SETTING: Community and institutional settings in Canada. SUBJECTS: Individuals who underwent a clinical evaluation (N = 2914). INTERVENTION: Initial screening with the Modified Mini-Mental State Examination (3MS) to identify potential cognitive impairment; the 3MS was followed by a detailed clinical examination to confirm the presence of dementia and to determine the probable cause. Clinical examinations were performed on all those subjects who were residing in institutions, those in the community with a 3MS score less than 78, and a sample of those in the community with a 3MS score of 78 or more. Neuropsychological testing was performed as part of the clinical examination when the 3MS score was 50 or more. At the conclusion of the assessment, subjects were categorized as being cognitively normal, CIND, and demented. MEASUREMENTS: Frequency of a diagnosis of CIND; demographical, cognitive, and functional characteristics of cognitively normal and CIND subjects and those with early and late dementia; and proportion of subjects who were CIND and met the proposed criteria. RESULTS: Subjects who were categorized as CIND were common and fell between cognitively normal subjects and those with dementia in terms of age, 3MS score, general intellectual function, and performance of daily activities. Because of the restrictive inclusion and exclusion criteria, the proposed criteria for cognitive impairment described only 30% of our subjects who were CIND. CONCLUSIONS: Subjects who were categorized as CIND appeared to be distinct from and intermediate between subjects with dementia and cognitively normal subjects. Most individuals did not meet the criteria that were evaluated for describing this group. While the various criteria that were evaluated may accurately define a select subset of cognitively impaired individuals, the natural history and prognosis of such groups, currently unknown, may not be generalizable to the larger population of subjects who are CIND. Further work is needed to clearly define this group, and longitudinal studies are required to determine an outcome.

Aged↗

PubMed1998

Peritonitis in the extended-care facility.

Many patients with end-stage renal disease (ESRD) require admission to an extended-care facility (ECF). Few data are available concerning the development of peritonitis among continuous peritoneal dialysis (CPD) patients residing in an ECF. We retrospectively reviewed the charts of 77 CPD patients admitted to an ECF between November 1993 and 31 August 1997. A total of 25 episodes of peritonitis developed among CPD patients in the ECF during this period for an overall peritonitis rate of 1 episode in 19.8 patient-months. The CPD patients developing peritonitis in the ECF were similar in age and gender to the CPD patients residing in the ECF not developing peritonitis. There were more African-Americans among the group of CPD patients residing in the ECF who developed peritonitis than among the ECF residents who did not develop peritonitis (41% vs. 23%, respectively; P < 0.05). Patients developing peritonitis in the ECF resided in the ECF significantly longer than the remaining CPD patients not developing peritonitis in the ECF (106 vs. 77 days, respectively; P < 0.05). The overall rate of peritonitis in the ECF was lower than that seen in the community (1 episode in 19.8 patient-months vs. 1 episode in 10.0 patient-months, respectively). The rate of gram-positive peritonitis was lower than the rate of gram-positive peritonitis seen in the community setting (1 episode in 54.9 patient-months vs. 1 episode in 14.9 patient-months, respectively). The rate of culture-negative peritonitis was higher among the ECF patients than among patients developing community-acquired peritonitis (1 episode in 61.9 patient-months vs. 1 episode in 106.2 patient-months, respectively). The spectrum of organisms in the ECF was different than the spectrum noted among patients developing hospital-acquired peritonitis. Eleven of the 25 episodes of peritonitis were treated successfully at the ECF while the remaining 14 episodes of peritonitis were treated at an acute-care hospital. Continuous PD therapy was continued following 19 of the 25 episodes (76%), 1 patient transferred to hemodialysis, and 5 patients expired. We conclude that patients develop peritonitis in the ECF less frequently than in the community setting, with the spectrum of organisms different than the spectrum seen in the community and hospital settings. Seventy-six percent of the patients continue CPD therapy following an episode of peritonitis.

Aged↗

PubMed2003

Five-year follow-up of cognitive impairment with no dementia.

CONTEXT: The importance of early identification of dementia has prompted numerous investigations of mild cognitive impairment and the preclinical stages of progressive degenerative disorders. To date, there is limited information from large-scale studies regarding outcomes of persons specifically identified with cognitive impairment but no dementia (CIND). OBJECTIVES: To investigate outcomes for persons with no cognitive impairment (NCI) or CIND, focusing on its etiologic subcategories, from the Canadian Study of Health and Aging (CSHA) and to examine the predictive validity of a set of core features thought to be early manifestations of subsequent dementia. DESIGN: Five-year, longitudinal follow-up of all persons without dementia examined during the first phase of the CSHA in 1991. SETTING: Community and institutional settings. PARTICIPANTS: Population-based sample of 883 persons with NCI and 801 persons with CIND at the first phase of the CSHA. At follow-up, 517 persons with NCI (59%) and 327 persons with CIND (41%) were alive and received clinical diagnoses. MAIN OUTCOME MEASURES: Mortality, institutionalization, and clinical diagnoses using the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for dementia. RESULTS: Persons with CIND were more likely than those with NCI to die (49% vs 30%), to be admitted to facility care (29% vs 14%), or to receive diagnoses of dementia (47% vs 15%) at follow-up. Those subsequently diagnosed as having dementia were more likely to have had impaired memory, informant-reported change in memory, and functional impairment at baseline. CONCLUSIONS: Persons with CIND were more likely to have a negative outcome than persons with NCI during a 5-year interval. This was true across etiologic subcategories and suggests that the use of specific diagnostic criteria sets does not improve our identification of those who develop dementia compared with a broader, more inclusive approach. More factors contributed to the prediction of all forms of dementia than to AD, but the most accurate prediction was for those who remained dementia free.

Aged↗

PubMed1998

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

CONTEXT: Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials. OBJECTIVE: To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease. DESIGN: Randomized, blinded, placebo-controlled secondary prevention trial. SETTING: Outpatient and community settings at 20 US clinical centers. PARTICIPANTS: A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus. Mean age was 66.7 years. INTERVENTION: Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1380) or a placebo of identical appearance (n = 1383). Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years. MAIN OUTCOME MEASURES: The primary outcome was the occurrence of nonfatal myocardial infarction (MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease. All-cause mortality was also considered. RESULTS: Overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had MI or CHD death (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22). The lack of an overall effect occurred despite a net 11% lower low-density lipoprotein cholesterol level and 10% higher high-density lipoprotein cholesterol level in the hormone group compared with the placebo group (each P<.001). Within the overall null effect, there was a statistically significant time trend, with more CHD events in the hormone group than in the placebo group in year 1 and fewer in years 4 and 5. More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84 vs 62; RH, 1.38; 95% CI, 1.00-1.92). There were no significant differences in several other end points for which power was limited, including fracture, cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38). CONCLUSIONS: During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.

Aged↗

PubMed2002

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

CONTEXT: Raloxifene, a selective estrogen receptor modulator, improves cardiovascular risk factors, but its effect on cardiovascular events is unknown. OBJECTIVE: To determine the effect of raloxifene on cardiovascular events in osteoporotic postmenopausal women. DESIGN: Secondary analysis of data from the Multiple Outcomes of Raloxifene Evaluation trial, a randomized, double-blind, placebo-controlled trial conducted between November 1994 and September 1999. SETTING: Outpatient and community settings at 180 sites in 25 countries. PARTICIPANTS: A total of 7705 osteoporotic postmenopausal women (mean age, 67 years). INTERVENTION: Patients were randomly assigned to receive raloxifene, 60 mg/d (n = 2557), or 120 mg/d (n = 2572), or placebo (n = 2576) for 4 years. MAIN OUTCOME MEASURES: Cardiovascular events, including coronary events (myocardial infarction, unstable angina, or coronary ischemia) and cerebrovascular events (stroke or transient ischemic attack), collected as safety end points and subsequently adjudicated by a cardiologist blinded to therapy. Cardiovascular risk at study entry was determined by the presence of multiple cardiovascular risk factors or prior coronary events or revascularization procedure. RESULTS: In the overall cohort, there were no significant differences between treatment groups in the number of combined coronary and cerebrovascular events: 96 (3.7%) with placebo, 82 (3.2%) with 60 mg/d of raloxifene, and 94 (3.7%) with 120 mg/d of raloxifene. Relative risks (RRs) were 0.86 (95% confidence interval [CI], 0.64-1.15) and 0.98 (95% CI, 0.74-1.30) for 60 mg/d and 120 mg/d of raloxifene, respectively. Similar results were obtained when coronary and cerebrovascular events were analyzed separately. Among the subset of 1035 women with increased cardiovascular risk at baseline, those assigned to raloxifene had a significantly lower risk of cardiovascular events compared with placebo (RR, 0.60; 95% CI, 0.38-0.95 for both raloxifene groups). The number of cardiovascular events during the first year was not significantly different across groups in the overall cohort (P =.94), or among women at increased cardiovascular risk (P =.86) or with evidence of established coronary heart disease (P =.60). CONCLUSIONS: Raloxifene therapy for 4 years did not significantly affect the risk of cardiovascular events in the overall cohort but did significantly reduce the risk of cardiovascular events in the subset of women with increased cardiovascular risk. There was no evidence that raloxifene caused an early increase in risk of cardiovascular events. Before raloxifene is used for prevention of cardiovascular events, these findings require confirmation in trials with evaluation of cardiovascular outcomes as the primary objective.

Aged↗

PubMed1997

Age- and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population.

MAIN OBJECTIVE: To report age- and education-specific reference values for the Mini-Mental State Examination (MMSE) and Modified Mini-Mental State (3MS) Examination. DESIGN: Cross-sectional study. SETTING: Community and institutional settings in five regions across Canada. PARTICIPANTS: 7754 subjects aged 65 and over randomly chosen to take part in the Canadian Study of Health and Aging. Subjects classified as cognitively impaired or demented following a clinical and neuropsychological examination were excluded. MEASUREMENTS: Total scores on the MMSE and 3MS, and the degree to which they are influenced by the age, sex, education, mother tongue and living environment of the subject. RESULTS: Reference values on the two tests are reported through various descriptive statistics for five age groups and four education levels. These values decrease with age and increase with years of schooling. Test scores are also influenced by the subject's sex and mother tongue, albeit to a lesser extent. These observations led to the development of predictive equations of the performance to be expected from a 'normal' elderly subject, given his/her socio-demographic characteristics. CONCLUSION: The use of the reference values and related predictive equations will allow the clinician to interpret a patient's performance on two widely used cognitive tests, in light of the value expected from a group of 'normal' subjects with the same sociodemographic profile.

Age Factors↗

PubMed2005

Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus.

BACKGROUND: Research suggests adherence to treatment recommendations is low. In type 2 diabetes, which is a chronic condition slowly leading to serious vascular, nephrologic, neurologic and ophthalmological complications, it can be assumed that enhancing adherence to treatment recommendations may lead to a reduction of complications. Treatment regimens in type 2 diabetes are complicated, encompassing life-style adaptations and medication intake. OBJECTIVES: To assess the effects of interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from searches of multiple electronic bibliographic databases supplemented with hand searches of references. Date of last search: November 2002. SELECTION CRITERIA: Randomised controlled and controlled clinical trials, before-after studies and epidemiological studies, assessing changes in adherence to treatment recommendations, as defined in the objectives section, were included. DATA COLLECTION AND ANALYSIS: Two teams of reviewers independently assessed the trials identified for inclusion. Three teams of two reviewers assessed trial quality and extracted data. The analysis for the narrative part was performed by one reviewer (EV), the meta-analysis by two reviewers (EV, JW). MAIN RESULTS: Twentyone studies assessing interventions aiming at improving adherence to treatment recommendations, not to diet or exercise recommendations, in people living with type 2 diabetes in primary care, outpatient settings, community and hospital settings, were included. Outcomes evaluated in these studies were heterogeneous, there was a variety of adherence measurement instruments. Nurse led interventions, home aids, diabetes education, pharmacy led interventions, adaptation of dosing and frequency of medication taking showed a small effect on a variety of outcomes including HbA1c. No data on mortality and morbidity, nor on quality of life could be found. AUTHORS' CONCLUSIONS: Current efforts to improve or to facilitate adherence of people with type 2 diabetes to treatment recommendations do not show significant effects nor harms. The question whether any intervention enhances adherence to treatment recommendations in type 2 diabetes effectively, thus still remains unanswered.

Diabetes Mellitus, Type 2↗

PubMed1989

Community psychology in Hong Kong: past, present, and future.

The expansion of mental health services during the 1960s from a single remote mental hospital to centers and clinics in mainstream communities fostered the development of community psychology in Hong Kong. Few psychologists were initially involved in the local community mental health movement, but its momentum resulted in increasing numbers of practitioner psychologists working in community-based service settings. Community psychology in Hong Kong today consists primarily of service delivery, but also includes applied research, community organization/consultation, and community education. Despite having many parallels with the American situation, key concepts underpinning the practice of community psychology in the Territory possess their own character as a reflection of nuances in the local scene. Prospects for the continued development of community psychology in Hong Kong appear favorable. Of special relevance is the field's potential contribution to a better understanding of the psychological phenomena associated with the Territory's sociopolitical transformation in 1997.

Community Mental Health Services↗

PubMed2005

Tobacco advertising in communities: associations with race and class.

BACKGROUND: Individuals of lower socioeconomic position smoke at higher rates than those of higher socioeconomic position. Because of this disparity, the National Cancer Institute has called for studies of targeted tobacco marketing to clarify mechanisms contributing to higher tobacco use among low-income Americans and other high-risk populations. METHODS: We observed tobacco industry marketing in six Boston area communities (two of high socioeconomic position and four of low position; total of 41 observations) and in selected print publications that circulated in those communities during a 22-month period in 2000-2002. RESULTS: On average, there were fewer tobacco advertisements in the higher socioeconomic communities, compared to the lower socioeconomic communities (P < 0.001). In the low socioeconomic communities, there were more than three times as many brand advertisements as youth access signs (P = 0.0012). Although brand advertisements outnumbered smoke-free signs, on average, there was no difference in the ratio of brand advertisements to smoke-free signs in low and high socioeconomic communities (P = 0.06). CONCLUSIONS: The tobacco industry is actively present in community settings, particularly in communities with a low socioeconomic profile (SEP). Tobacco control researchers and advocates need to continue to monitor the tobacco industry's behavior at the community level and develop strategies to counter this behavior.

Advertising↗

PubMed2003

Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis.

OBJECTIVES: To explore coronary heart disease risk in a sample of women with multiple sclerosis (MS) by identifying the presence of established risk factors for coronary heart disease and to determine the relationship between disease severity and level of participation in health-related behaviors. DESIGN: Survey study. SETTING: Five general community settings in Oregon. PARTICIPANTS: Women with physician-diagnosed MS (N=123) recruited from MS chapters, physician referrals, and newspaper announcements. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Modified Yale Physical Activity Survey, Block Food Frequency Questionnaire, blood analysis, skinfolds, and waist and hip circumferences. RESULTS: The majority of women met current physical activity guidelines. The frequencies of unfavorable levels of metabolic variables and obesity were similar to those reported in the general population. Significant associations were observed between mobility and physical activity, total and abdominal fat, and several dietary habits. CONCLUSION: Coronary heart disease risk in this sample was comparable to that of the general population of women without MS. Physical inactivity, body composition, and perhaps nutritional habits decline with decreasing mobility, emphasizing the need for families and health care providers to work together to find solutions that increase health-promoting behaviors in women with more advanced MS.

Blood Glucose↗

PubMed1999

Assessment of arteriovenous blood flow during retrograde cerebral perfusion.

OBJECTIVE: This study examined arterial and venous blood flow during retrograde cerebral perfusion (RCP) to quantify what proportion of arterial inflow is not recovered as venous outflow. DESIGN: Prospective. SETTING: Community hospital, university setting, single institution. PARTICIPANTS: Twelve patients undergoing reconstructive aortic arch surgery with profound hypothermic circulatory arrest and RCP. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: RCP arterial inflow and venous outflow measurements were recorded at 2-minute intervals for 10 minutes, averaged, and then compared. Only 44.9%+/-16.3% of RCP inflow returned through the aortic arch. The remainder was not recovered. CONCLUSION: Internal jugular venous valves, sequestration, and shunting may contribute to arterial inflow diversion during RCP.

Aged↗

PubMed1999

Arterial and venous blood gas analyses during retrograde cerebral perfusion.

OBJECTIVE: To examine arterial and venous blood gas analyses during retrograde cerebral perfusion to quantify oxygen uptake and carbon dioxide production. DESIGN: Prospective. SETTING: Community hospital, university setting, single institution. PARTICIPANTS: Twelve patients undergoing reconstructive aortic surgery with profound hypothermic circulatory arrest and retrograde cerebral perfusion. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: After 10 minutes of retrograde cerebral perfusion, blood gas analysis (measured at 37 degrees C, without temperature correction) was performed on blood samples drawn simultaneously from the arterial inflow and venous return (collected via aortic arch vessels) sites. Compared with arterial blood samples, PO2 (deltaPO2: 431.2+/-154.9 mm Hg; p<0.05), pH (deltapH: 0.16+/-0.09, p<0.05) and base excess (deltaBE: 1.0+/-0.85; p<0.05) decreased in venous blood samples, whereas PCO2 increased (deltaPCO2: 18.2+/-8.8 mm Hg; p<0.05). An arteriovenous content difference of 2.5+/-1.9 mL/dL reflected a total oxygen extraction of 20.5%+/-15.7%, although most extraction occurred from oxygen in solution. CONCLUSION: These findings suggest that retrograde cerebral perfusion produces cerebral aerobic metabolism.

Aorta↗